Yescarta

Yescarta. It is a CAR T-cell therapy used as an immunotherapy for certain types of B-cell lymphoma. Developed by Kite Pharma, a subsidiary of Gilead Sciences, it involves genetically engineering a patient's own T cells to target and destroy cancer cells. The therapy received accelerated approval from the U.S. Food and Drug Administration in 2017, marking a significant advancement in the field of oncology.

Medical uses

Yescarta is indicated for the treatment of adult patients with large B-cell lymphoma that is refractory or in relapse after two or more lines of systemic therapy. This includes specific subtypes such as diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma. The approval was based on pivotal clinical trial results from the ZUMA-1 study, which demonstrated substantial response rates in this heavily pre-treated population. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Treatment with Yescarta is administered at certified healthcare facilities experienced in the management of cytokine release syndrome and neurologic toxicities.

Adverse effects

The most common severe adverse reactions associated with Yescarta are cytokine release syndrome and neurologic toxicities, which can be life-threatening. Symptoms of cytokine release syndrome may include high fever, hypotension, and hypoxia, while neurologic events can range from headache and encephalopathy to seizures and cerebral edema. Other frequent adverse events include infections, febrile neutropenia, and prolonged cytopenias. Due to these risks, the FDA requires a Risk Evaluation and Mitigation Strategy program, and the therapy carries a Boxed Warning regarding these potential toxicities. Management strategies involve close monitoring and the use of tocilizumab and corticosteroids.

Pharmacology

Yescarta is an autologous therapy where a patient's T lymphocytes are collected via leukapheresis and genetically modified. The process involves using a lentiviral vector to insert a chimeric antigen receptor gene that directs the T cells to express a receptor targeting the CD19 antigen, a protein found on the surface of B cells. Once reinfused, these engineered CAR T cells expand in the patient's body and recognize and eliminate CD19-positive malignant and normal B cells. The pharmacokinetics show rapid expansion of CAR T cells post-infusion, with persistence detectable in the blood for months. The mechanism leads to a profound depletion of B-cell lineage cells, necessitating monitoring for immunoglobulin levels and associated infections.

History and development

The development of Yescarta originated from research conducted at the National Cancer Institute under the direction of Dr. Steven A. Rosenberg. The commercial development was spearheaded by Kite Pharma, founded by Arie Belldegrun. The pivotal ZUMA-1 trial, a multicenter study conducted at institutions like the University of Texas MD Anderson Cancer Center, demonstrated high rates of durable response. Based on these results, Yescarta received its first approval from the FDA in October 2017, becoming the second CAR T-cell therapy approved in the United States, following tisagenlecleucel. Subsequent approvals were granted by the European Medicines Agency and other regulatory bodies worldwide. The acquisition of Kite Pharma by Gilead Sciences in 2017 further accelerated its global commercialization.

Society and culture

The approval of Yescarta was a landmark event in oncology, often cited alongside other immunotherapies like pembrolizumab as part of a new era in cancer treatment. Its high cost has sparked significant debate about the economics of healthcare and drug pricing, involving discussions among policymakers, insurers, and organizations like the Institute for Clinical and Economic Review. The therapy has been featured in media outlets such as The New York Times and has been the subject of patient advocacy narratives. The complex logistics of its autologous manufacturing process have also influenced discussions on the infrastructure of cell therapy centers and global health equity.

Category:Monoclonal antibodies Category:Antineoplastic drugs Category:Immunotherapy